OTLK 1.44 (+3.6%)
US69012T2069BiotechnologyBiotechnology

Outlook Therapeutics (OTLK) Stock Highlights

1.44 | +3.6%
2024-12-21 06:35:25
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Statistics

Range Today
1.34 1.47
Volume Today 722.6K
Range 1 Year
0.87 12.85
Volume 1 Year 171.34M
Range 3 Year
0.87 42.4
Volume 3 Year 228.33M
Range 10 Year
0.87 878.4
Volume 10 Year 301.67M

Highlights

Market Capitalization 149.5M (small)
Floating Shares 13.53M
Current Price 1.44
Price To Earnings -1.14
Earnings Per Share -5.89
Payout Ratio 0%

Performance

Latest +3.6%
1 Month -72.31%
3 Months -76%
6 Months -80.14%
1 Year -82%
3 Years -95%
5 Years -93.63%
10 Years -99.76%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.